These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36227902)

  • 1. APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model.
    Bath NM; Verhoven BM; Wilson NA; Zeng W; Zhong W; Coons L; Djamali A; Redfield RR
    PLoS One; 2022; 17(10):e0275564. PubMed ID: 36227902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.
    Bath NM; Ding X; Wilson NA; Verhoven BM; Boldt BA; Sukhwal A; Reese SR; Panzer SE; Djamali A; Redfield RR
    PLoS One; 2019; 14(2):e0211865. PubMed ID: 30735519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
    Wilson NA; Bath NM; Verhoven BM; Ding X; Boldt BA; Sukhwal A; Zhong W; Panzer SE; Redfield RR
    Transplantation; 2019 Jul; 103(7):1372-1384. PubMed ID: 30830041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model.
    Bath NM; Ding X; Verhoven BM; Wilson NA; Coons L; Sukhwal A; Zhong W; Redfield Iii RR
    PLoS One; 2019; 14(10):e0223889. PubMed ID: 31647850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization.
    Agarwal D; Luning Prak ET; Bharani T; Everly M; Migone TS; Cancro M; Allman D; Choe I; Kearns JD; Trofe-Clark J; Naji A; Kamoun M
    Transpl Immunol; 2021 Dec; 69():101465. PubMed ID: 34506905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection.
    Liao T; Shi X; Han F; Wang Y; Zeng W; Liu R; Yan Z; Xia R; Huang Z; Xu J; Miao Y
    J Heart Lung Transplant; 2024 Apr; 43(4):652-662. PubMed ID: 38070662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
    Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
    Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
    Kuppachi S; Holanda D; Gallegos S; Field EH
    Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.
    Kwun J; Page E; Hong JJ; Gibby A; Yoon J; Farris AB; Villinger F; Knechtle S
    Am J Transplant; 2015 Mar; 15(3):815-22. PubMed ID: 25675879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats.
    Tajima T; Hata K; Kusakabe J; Miyauchi H; Badshah JS; Kageyama S; Zhao X; Kim SK; Tsuruyama T; Kirchner VA; Watanabe T; Uemoto S; Hatano E
    Front Immunol; 2023; 14():1186653. PubMed ID: 37398677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Effects and Functional Mechanism of Intravenous Immunoglobulin in Preclinical Rat Renal Transplant Model of Antibody-Mediated Rejection.
    Yamanaka K; Imamura R; Nakazawa S; Kato T; Kakuta Y; Abe T; Okumi M; Nonomura N
    Transplant Proc; 2020; 52(6):1901-1905. PubMed ID: 32362462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The B Cell-Stimulatory Cytokines BLyS and APRIL Are Elevated in Human Periodontitis and Are Required for B Cell-Dependent Bone Loss in Experimental Murine Periodontitis.
    Abe T; AlSarhan M; Benakanakere MR; Maekawa T; Kinane DF; Cancro MP; Korostoff JM; Hajishengallis G
    J Immunol; 2015 Aug; 195(4):1427-35. PubMed ID: 26150532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-empting Antibody-Mediated Rejection: A Program of DSA Monitoring and Treatment Can Effectively Prevent Antibody Mediated Rejection.
    Gilbert A; Grafals M; Timofeeva O; Zaheer M; Karabala A; Rosen-Bronson S; Li D; Awwad M; Abrams P; Moore J; Javaid B; Verbesey J; Ghasemian S; Cooper M
    Clin Transpl; 2016; 32():93-101. PubMed ID: 28564526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathymic immunomodulation in sensitized rat recipients of cardiac allografts: requirements for allorecognition pathways.
    Stadlbauer TH; Schaub M; Magee CC; Kupiec-Weglinski JW; Sayegh MH
    J Heart Lung Transplant; 2000 Jun; 19(6):566-75. PubMed ID: 10867337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.
    Parsons RF; Vivek K; Redfield RR; Migone TS; Cancro MP; Naji A; Noorchashm H
    Transplant Rev (Orlando); 2010 Oct; 24(4):207-21. PubMed ID: 20655723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.